New combo therapy aims to outperform standard lung cancer pill
NCT ID NCT06838273
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests whether adding a new drug, BL-B01D1, to the standard pill osimertinib helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer growing. About 720 adults with this type of lung cancer will be randomly assigned to receive either the combination or osimertinib alone. The main goal is to see if the combination delays cancer progression better than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.